Clinical efficacy evaluation of treatment of different degrees of retinal vein occlusion with ranibizumab combined with an argon ion laser

Wang,Dingding; Wang,Xiaoyi; Wu,Kunfang; Wang,Juanjuan; Xu,Guihua; Chen,Zilin

doi:10.3892/etm.2018.7125

Clinical efficacy evaluation of treatment of different degrees of retinal vein occlusion with ranibizumab combined with an argon ion laser

Authors:
- Dingding Wang
- Xiaoyi Wang
- Kunfang Wu
- Juanjuan Wang
- Guihua Xu
- Zilin Chen
View Affiliations

Affiliations: Ophthalmological Center of Huizhou Municipal Central Hospital, Huizhou, Guangdong 516000, P.R. China
Published online on: December 21, 2018 https://doi.org/10.3892/etm.2018.7125
Pages: 1563-1568

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to evaluate the clinical efficacy of an intravitreal injection of ranibizumab combined with argon ion laser photocoagulation therapy in the treatment of different degrees of central retinal vein occlusion (CRVO). A total of 112 CRVO patients including 25 cases of trunk occlusion, 50 cases of branch occlusion and 37 cases of hemiretinal vein-occlusion were enrolled in this study. Patients were treated with an intravitreal injection of 0.5 mg ranibizumab, followed by argon ion laser photocoagulation therapy after 7 days. Patients were followed up for 6 months and the best corrected visual acuity (BCVA), central retinal thickness (CRT), macular edema, and surgical complications were compared. Compared with the control treated with 0.5 mg ranibizumab, the BCVA and macular edema improved while CRT was significantly reduced in all groups treated with 0.5 mg ranibizumab combined with the argon ion laser. Furthermore, no obvious complications were observed in these groups and the effects of ranibizumab combined with argon ion laser photocoagulation on branch occlusion group were the best. Intravitreal injection of ranibizumab combined with argon ion laser photocoagulation therapy has better safety and effectiveness in the treatment of different degrees of CRVO. The trial registration number is 2015-318 and date of registration is 12/10/2015.

View Figures

View References

1	Wittström E: Central retinal vein occlusion in younger Swedish adults: Case reports and review of the literature. Open Ophthalmol J. 11:89–102. 2017. View Article : Google Scholar : PubMed/NCBI
2	Yau JW, Lee P, Wong TY, Best J and Jenkins A: Retinal vein occlusion: An approach to diagnosis, systemic risk factors and management. Intern Med J. 38:904–910. 2008. View Article : Google Scholar : PubMed/NCBI
3	Nroev VV: Modern aspects of diabetic retinopathy and diabetic macularoedema treatment. Vestn Ross Akad Med Nauk. 1:61–65. 2012.
4	Kolar P: Risk factors for central and branch retinal vein occlusion: A meta-analysis of published clinical data. J Ophthalmol. 2014:7247802014. View Article : Google Scholar : PubMed/NCBI
5	Kuo JZ, Lai CC, Ong FS, Shih CP, Yeung L, Chen TL, Chen KJ and Wu WC: Central retinal vein occlusion in a young Chinese population: Risk factors and associated morbidity and mortality. Retina. 30:479–484. 2010. View Article : Google Scholar : PubMed/NCBI
6	Priluck IA, Robertson DM and Hollenhorst RW: Long-term follow-up of occlusion of the central retinal vein in young adults. Am J Ophthalmol. 90:190–202. 1980. View Article : Google Scholar : PubMed/NCBI
7	Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB and Klein R: Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol. 147:298–306. 2009. View Article : Google Scholar : PubMed/NCBI
8	Keshav BR, Zacharia G, Bhat VK, Joseph MK and Ideculla T: Laser therapy in diabetic macular edema. Oman Med J. 23:28–31. 2008.
9	Ashraf M, Souka AA and Singh RP: Central retinal vein occlusion: Modifying current treatment protocols. Eye (Lond). 30:505–514. 2016. View Article : Google Scholar : PubMed/NCBI
10	Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK and Gonzalez VH: SCORE Study Research Group: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5. Arch Ophthalmol. 127:1101–1114. 2009. View Article : Google Scholar : PubMed/NCBI
11	Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, et al: Ozurdex GENEVA Study Group: Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 118:2453–2460. 2011. View Article : Google Scholar : PubMed/NCBI
12	Sellam A, Glacet-Bernard A, Coscas F and Souied EH: Abnormal retinal artery perfusion and optical coherence tomography angiography. J Fr Ophtalmol. 40:353–362. 2017.(In French). View Article : Google Scholar : PubMed/NCBI
13	Vogl WD, Waldstein SM, Gerendas BS, Schmidt-Erfurth U and Langs G: Predicting macular edema recurrence from spatio-temporal signatures in optical coherence tomography images. IEEE Trans Med Imaging. 36:1773–1783. 2017. View Article : Google Scholar : PubMed/NCBI
14	Puche N, Glacet A, Mimoun G, Zourdani A, Coscas G and Soubrane G: Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: A retrospective study of 34 eyes. Acta Ophthalmol. 90:357–361. 2012. View Article : Google Scholar : PubMed/NCBI
15	Mete A, Saygili O, Mete A, Gungor K, Bayram M and Bekir N: Does ranibizumab (Lucentis^®) change retrobulbar blood flow in patients with neovascular age-related macular degeneration? Ophthalmic Res. 47:141–145. 2012. View Article : Google Scholar : PubMed/NCBI
16	Lucatto LFA, Magalhães-Junior O, Prazeres JMB, Ferreira AM, Oliveira RA, Moraes NS, Hirai FE and Maia M: Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion. Arq Bras Oftalmol. 80:97–103. 2017. View Article : Google Scholar : PubMed/NCBI
17	Ghasemi Falavarjani K, Iafe NA, Hubschman JP, Tsui I, Sadda SR and Sarraf D: Optical coherence tomography angiography analysis of the foveal avascular zone and macular vessel density after anti-VEGF therapy in eyes with diabetic macular edema and retinal vein occlusion. Invest Ophthalmol Vis Sci. 58:30–34. 2017. View Article : Google Scholar : PubMed/NCBI
18	Bitirgen G, Belviranli S, Malik RA, Kerimoglu H and Ozkagnici A: Effects of panretinal laser photocoagulation on the corneal nerve plexus and retinal nerve fiber layer in retinal vein occlusion. Eur J Ophthalmol. 27:591–595. 2017. View Article : Google Scholar : PubMed/NCBI
19	Pikkel YY, Sharabi-Nov A, Beiran I and Pikkel J: Comparison of anti-vascular endothelial growth factors, laser treatments and a combination of the both for treatment of central retinal vein occlusion. Int J Ophthalmol. 9:431–433. 2016.PubMed/NCBI
20	Patel A, Nguyen C and Lu S: Central retinal vein occlusion: A review of current evidence-based treatment options. Middle East Afr J Ophthalmol. 23:44–48. 2016. View Article : Google Scholar : PubMed/NCBI
21	Yeh S, Kim SJ, Ho AC, Schoenberger SD, Bakri SJ, Ehlers JP and Thorne JE: Therapies for macular edema associated with central retinal vein occlusion: A report by the American Academy of Ophthalmology. Ophthalmology. 122:769–778. 2015. View Article : Google Scholar : PubMed/NCBI
22	Zhang L, Ke Y, Wang W, Shi X, Hei K and Li X: The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats' disease. Graefes Arch Clin Exp Ophthalmol. 256:1339–1346. 2018. View Article : Google Scholar : PubMed/NCBI
23	Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E, Das Gupta A, Wenzel A and Pearce I: BRIGHTER Study Group: Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER Study. Ophthalmology. 124:1778–1787. 2017. View Article : Google Scholar : PubMed/NCBI
24	Bertelmann T, Frank HU, Fuchs HA and Feltgen N: Branch retinal vein occlusion, macular ischemia, and intravitreal anti-VEGF therapy. Case Rep Ophthalmol. 8:271–278. 2017. View Article : Google Scholar : PubMed/NCBI
25	Ehlers JP, Kim SJ, Yeh S, Thorne JE, Mruthyunjaya P, Schoenberger SD and Bakri SJ: Therapies for macular edema associated with branch retinal vein occlusion: A report by the american academy of ophthalmology. Ophthalmology. 124:1412–1423. 2017. View Article : Google Scholar : PubMed/NCBI
26	Sakanishi Y, Usui-Ouchi A, Tamaki K, Mashimo K, Ito R and Ebihara N: Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab. Clin Ophthalmol. 11:829–834. 2017. View Article : Google Scholar : PubMed/NCBI
27	Chung CY and Li KKW: Optical coherence tomography angiography wide-field montage in branch retinal vein occlusion before and after anti-vascular endothelial-derived growth factor injection. Int Ophthalmol. 38:1305–1307. 2018. View Article : Google Scholar : PubMed/NCBI